Zembowicz A, Tang J L, Wu K K
Vascular Biology Research Center, University of Texas Houston Health Science Center 77030, USA.
J Biol Chem. 1995 Jul 14;270(28):17006-10. doi: 10.1074/jbc.270.28.17006.
Endothelial synthesis of NO is catalyzed by constitutive NO synthase type III (NOS-III). NOS-III has been thought to be regulated mainly at the level of enzyme activity by intracellular calcium. We report that in human umbilical vein endothelial cells lysophosphatidylcholine (lyso-PC), a component of atherogenic lipoproteins and atherosclerotic lesions, increases NOS-III mRNA and protein levels. This leads to the augmentation of NOS-III activity and the enhancement of antiplatelet properties of endothelial cells. Importantly, nuclear run-off experiments demonstrate a transcriptional mechanism of regulation of NOS-III expression by lysophosphatidylcholine. As endothelium-derived NO appears to be an anti-atherogenic molecule, induction of NOS-III by lyso-PC may be a protective response that limits the progress of the atherosclerotic lesion and promotes its regression.
一氧化氮(NO)的内皮合成由组成型III型一氧化氮合酶(NOS-III)催化。一直以来,人们认为NOS-III主要在细胞内钙的作用下通过酶活性水平进行调节。我们报告称,在人脐静脉内皮细胞中,溶血磷脂酰胆碱(lyso-PC)是致动脉粥样硬化脂蛋白和动脉粥样硬化病变的一个组成部分,它可增加NOS-III的mRNA和蛋白质水平。这导致NOS-III活性增强以及内皮细胞抗血小板特性增强。重要的是,核转录实验证明了溶血磷脂酰胆碱对NOS-III表达的转录调控机制。由于内皮源性NO似乎是一种抗动脉粥样硬化分子,lyso-PC对NOS-III的诱导可能是一种保护性反应,可限制动脉粥样硬化病变的进展并促进其消退。